Tag Archives: gent

Compound derived from vegetables shields rodents from lethal radiation doses

Their study, published today in the Proceedings of the National Academy of Sciences (PNAS) suggests the compound, already shown to be safe for humans, may protect normal tissues during radiation therapy for cancer treatment and prevent or mitigate sickness caused by radiation exposure. The compound, known as DIM (3,3′-diindolylmethane), previously has been found to have cancer preventive properties. "DIM has been studied as a cancer prevention agent for years, but this is the first indication that DIM can also act as a radiation protector," says the study’s corresponding author, Eliot Rosen, MD, PhD, of Georgetown Lombardi Comprehensive Cancer Center. For the study, the researchers irradiated rats with lethal doses of gamma ray radiation…

Realistic 3-d tumor created through tissue engineering using silk scaffolds

The team comprised Professor James Goh, Associate Professor Toh Siew Lok and Dr Pamela Tan from the Department of Bioengineering at NUS Faculty of Engineering, and Associate Professor Saminathan Suresh Nathan from the Department of Orthopaedic Surgery at the NUS Yong Loo Lin School of Medicine, who carried out their study using osteosarcoma, which is the most prevalent form of paediatric primary bone cancer. Reconstructing tumours in the laboratory has been a hot topic for research as current methods of testing have not been sufficient to yield concrete results. Dr Tan, who has been researching on the 3-D model for her PhD thesis, said: "Despite the urgent need to develop cancer therapeutics, little progress has been made due to the lack of good pre-clinical drug testing models. …

Research for Her: Bridging the gender gap in health studies

Before Kelli Sargent’s mother, Nanci, was diagnosed with stage 3C ovarian cancer in 2000, she and her family knew little about the disease’s warning signs. Frustrated by the lack of research and awareness surrounding ovarian cancer, Sargent and her mother started a nonprofit called “Run for Her” in conjunction with Cedars-Sinai Medical Center in 2005. The event, a 5,000-meter run held in Los Angeles, raises funds and spreads awareness about ovarian cancer. Though Nanci lost her battle with ovarian cancer five years ago, Run for Her is still dedicated to its mission. Now, a new program at Cedars-Sinai called Research for Her is collaborating with Run for Her to overcome another obstacle standing in the way of improved outcomes for ovarian cancer patients: the lack of women participating in clinical trials. Women are historically underrepresented in clinical trials and erasing this gender gap could help scientist’s develop better screening methods for diseases like ovarian cancer – something that Sargent believes could have saved her mother’s life. “If you catch ovarian cancer early…it’s basically curable. You have such an optimistic future,” Sargent told FoxNews.com. “But only less than 20 percent of cases are caught early.” Sign up, save lives While doctors are uncertain why fewer women choose to enroll in clinical trials, they know unequal gender representation in studies can have serious health implications. “If we don’t find out how drugs work in the real population, then they may simply not work as well as we hope that we do,” Dr. BJ Rimel, co-founder of Research for Her and a gynecologic oncologist in the department of obstetrics and gynecology at Cedars-Sinai, told FoxNews.com. Furthermore, the lack of female research participants has slowed studies seeking to explore the basic causes and markers of diseases like ovarian cancer.  Understanding the basic mechanisms behind these disorders could help lead to earlier detection methods – and ultimately save lives. It wasn’t until Rimel began her career at Cedars-Sinai in 2011, with a dream of conducting clinical trials, that she understood the severity of the problem. “I realized the enrollment for clinical trials at Cedars was abysmal,” Rimel said. “We weren’t making a dent. We were offering all these great things, but nothing was happening.” Rimel eventually met Dr. Catherine Deng, associate director of the Wasserman Breast Cancer Risk Reduction Program and surgeon at the Saul and Joyce Brandman Breast Center at Cedars-Sinai, who was having difficulty getting women to sign up for her breast cancer registry. With help from the already established Run for Her, the two women joined forces and launched the Research for Her clinical trial online registry. Doctors suspect that women haven't signed up for clinical trails in the past because of a lack of information, or because of the difficult sign-up process. Previously, the registration process for clinical trials was cumbersome, done primarily in the doctor’s office and using pen and paper.   “Women aren’t going to seek out a clinical trial when they have 19 other things to do, just to figure out if they qualify,” Sargent said. But with Research for Her, the sign-up process is easy. It takes only about 10 minutes, can be done online and all medical information is confidential, according to Rimel. If a woman qualifies for a trial, a research coordinator will contact her personally with more information – though there is no obligation to participate. “We want to make this simple,” Rimel said. And they seem to be on to something. Since the program’s launch on March 18, Research for Her has succeeded in registering 160 women for clinical trials – a huge increase for the program. Promising research One exciting trial currently benefitting from the Research for Her registry seeks to pinpoint chemical markers in the blood that may act as early identifiers for ovarian cancer. “We are trying to enroll women in the study (that are) already at risk for ovary cancer. The general population has a low risk, but for women with a high risk, we don’t know how best to screen them,” Rimel said. Thanks to the registry, researchers have been able to connect with a larger pool of women eligible to participate in the trial. “This registry has allowed us to find these women and contact them and get people in the study…that we haven’t been able to fill before now,” Rimel said.   Ultimately, Rimel and Deng hope to register 2,000 women through Research for Her by the end of the year. But in the long term, Rimel hopes that the program will be used nationwide to boost participation in clinical trials and further the progress of medical research. “Right now, it’s a single institution, but we hope if this takes off that we can network with others to make it a real way to help people (get) in clinical trials,” Rimel said. “That is my dream for this.” Sargent hopes that getting the word out about registry will help improve detection and treatment methods for women’s cancers – and save other women battling the disease that their mothers fought. “There is so much to learn, especially as research is advancing,” Sargent said. “They need this information from women.” Click for more on Research for Her. source : http://www.foxnews.com/health/2013/06/04/research-for-her-bridging-gender-gap-in-health-studies/

High doses of common painkillers increase heart attack risks

Long-term high-dose use of painkillers such as ibuprofen or diclofenac is “equally hazardous” in terms of heart attack risk as use of the drug Vioxx, which was withdrawn due to its potential dangers, researchers said on Thursday. Presenting the results of a large international study into a class of painkillers called non-steroidal anti-inflammatory drugs (NSAIDs), the researchers said high doses of them increase the risk of a major vascular event - a heart attack, stroke or dying from cardiovascular disease - by around a third. This means that for every 1,000 people with an average risk of heart disease who take high-dose diclofenac or ibuprofen for a year, about three extra would have an avoidable heart attack, of which one would be fatal, the researchers said. This puts the heart risks of generic NSAIDs on a par with a newer class of NSAIDs known as COX-2 inhibitors or coxibs, which includes Vioxx - a painkiller that U.S. drugmaker Merck pulled from sale in 2004 because of links to heart risks. Other drugs in the coxib class include cerecoxib, sold by Pfizer under the brand name Celebrex, and etoricoxib, sold by Merck under the brand name Arcoxia. “What we are saying is that they (coxibs, ibuprofen and diclofenac) have similar risks, but they also have similar benefits,” said Colin Baigent of the clinical trial service unit at Britain's Oxford University, who led the study published in The Lancet medical journal on Thursday. He stressed that the risks are mainly relevant to people who suffer chronic pain, such as patients with arthritis who need to take high doses of painkillers - such as 150mg of diclofenac or 2400mg of ibuprofen a day - for long periods. “A short course of lower dose tablets purchased without a prescription, for example, for a muscle sprain, is not likely to be hazardous,” he said. BALANCING RISKS AND BENEFITS The study team gathered data, including on admissions to hospital for cardiovascular or gastrointestinal disease, from all randomized trials that have previously tested NSAIDs. This allowed them to pool results of 639 randomized trials involving more than 300,000 people and re-analyze the data to establish the risks of NSAIDs in certain types of patients. In contrast to the findings on ibuprofen and diclofenac, the study found that high doses of naproxen, another NSAID, did not appear to increase the risk of heart attacks. The researchers said this may be because naproxen also has protective effects that balance out any extra heart risks. Baigent said it was important patients should not make hasty decisions or change their treatment without consulting a doctor. “For many arthritis patients, NSAIDs reduce joint pain and swelling effectively and help them to enjoy a reasonable quality of life,” he said. “We really must be careful about the way we present the risks of these drugs. “They do have risks, but they also have benefits, and patients should be presented with all those bits of information and allowed to make choices for themselves.” Donald Singer, a professor of clinical pharmacology and therapeutics at Britain's Warwick University, who was not involved in the study, said its findings “underscore a key point for patients and prescribers: powerful drugs may have serious harmful effects”. “It is therefore important for prescribers to take into account these risks and ensure patients are fully informed about the medicines they are taking,” he said in an emailed comment.source : http://www.foxnews.com/health/2013/05/30/high-doses-common-painkillers-increase-heart-attack-risks/

Chaga: A potent immune enhancing fungus

Recently my wife and I were walking in the woods when I spotted a rotting birch tree. All over the decaying trunk were clusters of a gnarly black growth, which I quickly recognized as chaga (Inonotus obliquus).  Relatively unused in the west, chaga is a potent immune enhancing agent that is highly popular in Russia and parts of Europe, and it enjoys a major body of science for its health benefits. Unlike most fungus, chaga is hard and woody, bearing no resemblance to mushrooms. Instead, it looks more like a cracked piece of burned charcoal. Chaga’s black color is due to a concentration of melanin, the same pigment that colors human skin. Because chaga can be used to start fires, it is also known as the “tinder fungus.” The name chaga derives from the Komi-Permyak language of Russia’s Kama River Basin, where the fungus has played a role in traditional medicine for centuries. Chaga can be found throughout northern Asia and in Canada, Norway, northern and eastern Europe and northern parts of the United Sates. Chaga is rich in natural antioxidant and anti-inflammatory phenols, containing the compounds betulin and betulinic acid – which derive directly from host birch trees. Both betulin and betulinic acid demonstrate anti-tumor effects, which explain why chaga is known as an anti-cancer agent. Additionally, some science shows that betulin can play a beneficial role in controlling metabolic disorders, such as obesity and metabolic syndrome. A group of compounds in chaga called lanostanoids also appear to play significant anti-cancer roles. The exact anti-cancer activity of chaga is not completely understood, but some compounds in the fungus boost immune activity, some specifically prevent cancer cells from replicating, and others cause premature cancer cell death. This argues for the utilization of a whole chaga extract, rather than isolating a single compound. In chaga, many agents appear to be active against cancer. One of the most surprising benefits of chaga is in regards to psoriasis. In one Russian study, psoriasis patients who took chaga recovered from their condition. Given that psoriasis is notoriously difficult to treat and responds to very little therpaies, this effect alone could be of enormous benefit to many. The compound ergosterol in chaga, along with related agents, shows anti-inflammatory activity. This may account for why chaga is thought of as a life-extending agent in China, as inflammation is part of every chronic, degenerative disease. Reducing systemic inflammation can mitigate or help prevent a variety of health problems, leading to a healthier life – and presumably a longer one. Traditionally, chaga has been used for a variety of purposes. Scientific investigation chaga’s use as an anti-allergy agent shows that in animals, the fungus has the ability to prevent anaphylactic shock – a serious and potentially fatal consequence of a severe allergy. In another study, administration of an extract of chaga reduced infection due to the Herpes simplex virus. In a cell study, chaga showed potent activity against the hepatitis C virus. Whether this same activity will prove true in living humans remains to be seen, but if it does, then chaga will benefit thousands of people who often suffer for many years with this crippling disease. Chaga products are widely available in natural food stores and on the Internet. One chaga product I like is made in Vermont and is available at www.Mariefrohlich.com. Considering that spring is here and chaga demonstrates value against allergies, this may be an excellent time to try chaga, whose nickname “Mushroom of Immortality” appears to be far more than just a clever slogan.Chris Kilham is a medicine hunter who researches natural remedies all over the world, from the Amazon to Siberia. He teaches ethnobotany at the University of Massachusetts Amherst, where he is Explorer In Residence. Chris advises herbal, cosmetic and pharmaceutical companies and is a regular guest on radio and TV programs worldwide. His field research is largely sponsored by Naturex of Avignon, France. Read more at& MedicineHunter.com.source : http://www.foxnews.com/health/2013/05/29/chaga-potent-immune-enhancing-fungus/

Shape-shifting nanoparticles flip from sphere to net in response to tumor signal

Spherical nanoparticles labeled with red or green dye shift their shapes and accumulatte into netlike structures when they encounter a protease secreted by some kinds of cancerous tumors (Click on image for larger view). Targeting treatments specifically to cancerous or other diseased cells depends on some means of accumulating high levels of a drug or other therapeutic agent at the specific site and keeping it there. Most efforts so far depend on matching a piece of the drug-delivering molecule to specific receptors on the surface of the target cell. …

Novel class of drugs for prostate cancers

In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling, which is driven by androgens, such as testosterone. To thwart tumor growth, most patients with advanced prostate cancer receive drugs that block the production of androgen or block the receptor where the androgen binds. Unfortunately, such treatments invariably fail and patients die of prostate cancer with their androgen receptor signaling still active and still promoting tumor growth. In the new study, available online at Nature Communications, a team of researchers led by Dr. …